VTCN1 and osteosarcoma: To evaluate this, we assayed four different human cancer cell lines (MDA MB 468 [breast], SKBR3 [breast], U2OS [osteosarcoma], OVCAR4 [ovary]) for their expression of endogenous B7x and stimulated each with the pro-inflammatory cytokine IFNγ, TNFα, or the anti-inflammatory cytokine IL-10 to evaluate potential change in expression following this stimulation based on current literature suggesting these cytokines regulate B7x on subsets of antigen-presenting cells (APCs) [27–30].